SCHEMBL5027265

SCHEMBL5027265

COc1ccccc1-c1cccc(C(=O)NCC(=O)NC2CCC(NC(C)(C)C)CC2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
HPGD P15428 3/20 0.56
CTSA P10619 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44
APEX1 P27695 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
RAB9A P51151 3/20 0.43
NPC1 O15118 2/20 0.43
GAA P10253 1/20 0.41
UGCG Q16739 1/20 0.41
ADORA3 P0DMS8 1/20 0.40
ADORA1 P30542 1/20 0.40
CNR2 P34972 1/20 0.40
KCNA3 P22001 1/20 0.39
CCR2 P41597 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5027275 1.00 ALDH1A1 (0.56) ALDH1A1HPGDCTSASMN1; SMN2KDM4E
SCHEMBL5029598 0.79 RAB9A (0.43) RAB9ANPC1CNR2CCR2
SCHEMBL5033653 0.79 CCR2 (0.51) MEN1KMT2ARAB9ANPC1CCR2
SCHEMBL5033656 0.79 CCR2 (0.51) MEN1KMT2ARAB9ANPC1CCR2
SCHEMBL5030277 0.79 RAB9A (0.46) ALDH1A1HPGDMEN1KMT2ARAB9A
SCHEMBL5030274 0.79 RAB9A (0.46) ALDH1A1HPGDMEN1KMT2ARAB9A
SCHEMBL5033733 0.79 CNR2 (0.45) RAB9ACNR2CCR2
SCHEMBL5029445 0.76 CTSA (0.45) CTSARAB9AADORA1CNR2CCR2
SCHEMBL5029439 0.76 CTSA (0.45) CTSARAB9AADORA1CNR2CCR2
SCHEMBL5031756 0.72 RAB9A (0.40) KMT2ARAB9ANPC1CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7378409-B2 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-27 US disclosed
US-20050054626-A1 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054626-A1 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity CCL11, CCR1, CCR2 ALDH1A1 827/4885HPGD 2035/4885CTSA 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.